REGAIN STUDY: Retrospective Study to Assess the Effectiveness, Tolerability, and Safety of Ferric Carboxymaltose in the Management of Iron Deficiency Anemia in Pregnant Women

Iron deficiency anemia (IDA) during pregnancy arises because of preexisting inadequate stores or complex physiological changes and can lead to serious maternal and fetal complications. Oral iron, either as iron sulfate or fumarate, with or without folic acid, is the most commonly used treatment for IDA in pregnancy. Intravenous (IV) iron has a role in the treatment of IDA in pregnancy, particularly in women who present late, display severe anemia (Hb ≤ 9 g/dL), or risk factors, and are intolerant/noncompliant of oral iron. Previously, administration of IV iron was minimal, owing to potentially serious anaphylactic reactions. Recently, new IV iron products have been developed, offering better compliance, tolerability, efficacy, and a good safety profile. Our study aimed to assess the effectiveness, safety, and tolerability of IV ferric carboxymaltose (FCM) in the treatment of IDA in pregnant women in the UAE. Data from 1001 pregnant women who received at least one administration of FCM (500, 1000, or 1500 mg) during their second or third trimester of pregnancy (2 years backward from study initiation) were collected retrospectively from electronic medical records at Corniche Hospital, Abu Dhabi, UAE. Results showed that 41.4% of the women were able to achieve an increase of ≥2 g/dL in blood hemoglobin overall. A change of ≥2 g/dL was achieved by 27.5% of women administered a dose of 500 mg, 39.2% of women administered a dose of 1000 mg, and 63.9% of women administered a dose of 1500 mg of IV FCM. This indicates a directly proportional relationship between increasing IV FCM dose and the increase of ≥2 g/dL in blood hemoglobin. A total of 7 (0.7%) women reported mild, nonserious adverse events during the study. Within the limits of this retrospective study, IV FCM therapy was safe and effective in increasing the mean hemoglobin of pregnant women with IDA.

[1]  R. Saxena,et al.  Comparison of ferric Carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy- randomised controlled trial , 2019, BMC Pregnancy and Childbirth.

[2]  J. Allen,et al.  A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy. , 2018, Seminars in hematology.

[3]  J. Jun,et al.  Efficacy and safety of ferric carboxymaltose versus ferrous sulfate for iron deficiency anemia during pregnancy: subgroup analysis of Korean women , 2018, BMC Pregnancy and Childbirth.

[4]  R. Grivell,et al.  Use of intravenous iron polymaltose in the management of iron deficiency in pregnancy: A retrospective cohort study , 2018, The Australian & New Zealand journal of obstetrics & gynaecology.

[5]  G. Bader,et al.  Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials , 2018, BMC Women's Health.

[6]  S. D. Joshi,et al.  Comparative study of efficacy and safety of intravenous ferric carboxy maltose versus iron sucrose in treatment of postpartum iron deficiency anemia , 2016 .

[7]  W. Ganzevoort,et al.  Safety and Efficacy of Ferric Carboxymaltose in Anemic Pregnant Women: A Retrospective Case Control Study , 2015, Obstetrics and gynecology international.

[8]  O. Api,et al.  Diagnosis and treatment of iron deficiency anemia during pregnancy and the postpartum period: Iron deficiency anemia working group consensus report , 2015, Turkish journal of obstetrics and gynecology.

[9]  C. Gasche,et al.  Management of Iron Deficiency Anemia. , 2015, Gastroenterology & hepatology.

[10]  V. Mishra,et al.  Study of intravenous ferric carboxy maltose in iron deficiency anemia in women attending gynecological clinic - safety and efficacy , 2015 .

[11]  N. Hodyl,et al.  Intravenous ferric carboxymaltose for anaemia in pregnancy , 2014, BMC Pregnancy and Childbirth.

[12]  I. Hussain,et al.  Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia , 2013, Anemia.

[13]  M. Ball,et al.  Three-year follow-up of a randomised clinical trial of intravenous versus oral iron for anaemia in pregnancy , 2012, BMJ Open.

[14]  O. Irion,et al.  Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose , 2012, Journal of perinatal medicine.

[15]  B. Myers,et al.  Comparative efficacy and safety of intravenous ferric carboxymaltose (Ferinject) and iron(III) hydroxide dextran (Cosmofer) in pregnancy , 2012, Obstetric medicine.

[16]  G. Bailie.  Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications , 2010, Arzneimittelforschung.

[17]  Kuo-Chin Huang,et al.  The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study , 2010 .

[18]  A. Urato.  Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. , 2008, Obstetrics and gynecology.

[19]  A. Mangione,et al.  Intravenous Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Postpartum Anemia: A Randomized Controlled Trial , 2007, Obstetrics and gynecology.

[20]  E. Sheiner,et al.  Anemia during pregnancy and treatment with intravenous iron: review of the literature. , 2003, European journal of obstetrics, gynecology, and reproductive biology.

[21]  N. Milman,et al.  Iron status and iron balance during pregnancy. A critical reappraisal of iron supplementation , 1999, Acta obstetricia et gynecologica Scandinavica.

[22]  A. Wynne-Jones.  The treatment of iron-deficiency anaemia of pregnancy. , 1967, The Journal of the College of General Practitioners.